What did @dr.michaelmoeller actually say?
The creator made two specific statistical claims: that 25% of men by age 30 have low testosterone, and that 40% of men by age 45 have low testosterone. He attributed both figures to the Cleveland Clinic, though his caption credits the 25% figure to Western Michigan Urological Associates. He also suggested that clinical reference ranges have been lowered over time, and drew a pointed comparison to hormone therapy in teenage girls.
To his credit, he's not making vague wellness claims here. He's citing specific numbers, naming sources, and making a policy argument. That's worth engaging with seriously, not dismissing. But sourcing matters, and the numbers he's using deserve scrutiny before anyone takes them as settled fact.
Does the science back this up?
Partially, but the picture is messier than the video lets on. The prevalence of low testosterone depends almost entirely on how you define it, and that's where things get complicated.
The most widely cited population study, by Araujo et al. (2007, Journal of Clinical Endocrinology and Metabolism), found that about 39% of men aged 45 and older had testosterone levels below 300 ng/dL. That's in the ballpark of the 40% figure the creator cites. However, symptomatic hypogonadism, meaning low T plus clinical symptoms, was found in only about 5.6% of that same group. A biochemical number below a threshold is not the same as a diagnosable condition.
The 25% figure for men over 30 is harder to pin down in peer-reviewed literature. A study by Travison et al. (2007, Journal of Clinical Endocrinology and Metabolism) documented a population-level decline in testosterone over recent decades, which lends some credibility to the broader alarm the creator is sounding. But 25% at age 30 is a stretch without a clear citation.
His claim that reference ranges have been lowered is partially accurate. Different labs use different cutoffs, and there has been genuine debate in endocrinology about where the threshold should sit. The Endocrine Society guidelines define hypogonadism as a consistently low morning testosterone below 300 ng/dL, but some labs previously used higher thresholds.
What did they get wrong (or right)?
He got the ballpark right on the 40% figure for men over 45, if you're counting everyone below a biochemical threshold. That number has epidemiological support. He deserves credit for pointing to a real and underappreciated issue in men's health.
What he got wrong, or at least sloppy with, is conflating low lab values with a clinical condition requiring treatment. Those are not the same thing. A man with testosterone at 295 ng/dL and no symptoms is not the same patient as a man at 280 ng/dL with fatigue, low libido, and loss of muscle mass. The creator doesn't make that distinction, and that omission matters.
The attribution is also shaky. He says "this is the Cleveland Medical Clinic" as his authority for both statistics, but the Cleveland Clinic's published materials cite different figures depending on the source page, and neither statistic maps cleanly to a single peer-reviewed publication the clinic produced. Citing a hospital's website is not the same as citing a clinical study.
The comparison to hormone therapy in 14-year-old girls is provocative but logically weak. Pediatric hormone therapy for gender dysphoria or precocious puberty involves completely different clinical contexts, risk profiles, and regulatory frameworks. The comparison generates heat but not light.
What should you actually know?
Low testosterone is real, it is underdiagnosed in some populations, and the stigma around men seeking treatment for it is genuinely counterproductive. Those points are fair.
But the 40% statistic, even when supported by research, describes biochemical measurements below a cutoff, not 40% of men walking around who need testosterone therapy. Diagnosis of hypogonadism requires two separate morning blood draws showing low testosterone, plus clinical symptoms. The Endocrine Society's 2018 clinical practice guidelines (Bhasin et al., Journal of Clinical Endocrinology and Metabolism) are explicit on this point.
There are also real risks to testosterone replacement therapy that a video like this doesn't mention: erythrocytosis, suppression of natural testosterone production, reduced fertility, and cardiovascular considerations that are still being studied. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) found TRT did not increase major cardiovascular events in men with hypogonadism, which is meaningful reassurance, but that doesn't mean TRT is appropriate for every man with a borderline lab result.
- Get two morning blood draws before any diagnosis is made
- Symptoms matter as much as numbers
- TRT affects fertility and should be discussed with a provider before starting
- Lifestyle factors including sleep, weight, and alcohol significantly affect testosterone levels